id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-1367	Avasarala, Jagannadha	Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill	2017	3	.pdf	application/pdf	2230	110	51	There is minimal scientific validity in infusing the drug every 6 months particularly if CD20 cell counts are negligible in the peripheral blood. Because OCR avidly targets CD20 cell populations and depletes them and as their numbers can be monitored by peripheral blood counts of CD19 cells, it remains poorly understood why OCR needs to be reinfused at sched- uled intervals regardless of CD20 cell counts.	cache/dti-1367.pdf	txt/dti-1367.txt